KING OF PRUSSIA, Pa.— Dec. 7, 2015 — Genomind, a personalized medicine company bringing innovation to mental health care through genetic testing, has appointed Zia Choudhry, M.D., Ph.D. as its Chief Medical Officer.
Dr. Choudhry previously served as the Medical Director of Scientific Affairs and Research at Premier Psychiatric Group in Lincoln, Neb.
Genomind’s Genecept Assay® is a comprehensive genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects.
“I look forward to joining the Genomind team as it continues to focus on personalized medicine for brain health,” says Choudhry. “Genomind is clearly on the cutting-edge of this revolutionary effort that is helping clinicians move from treating the illness to treating the individual.”
Dr. Choudhry received his Medical degree from the University of Karachi, Pakistan and pursued a family medicine residency with a focus on psychiatry. He holds a Master of Health Informatics from SZAB Institute of Science and Technology; a Master of Business Administration from AlKhair University; a Master of Sciences in Psychiatry from McGill University and Douglas Mental Health University Institute (DMHUI); and a Doctorate of Philosophy in Human Genetics from McGill University and DMHUI. He previously served as a Medical Advisor and Product Physician at Pfizer.
“As Genomind continues to grow and find more and more acceptance from clinicians, it’s essential that we continue to innovate and remain on the forefront of translating advances in genomic research to actual clinical care. Dr. Choudhry is perfectly suited to assist Genomind in this effort, given his vast expertise in genetics, psychiatric research and clinical care.” says Michael Koffler, Genomind’s President and CEO.
The Genecept Assay® is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, OCD, ADHD, bipolar disorder, PTSD, autism and schizophrenia.
Peer-reviewed published studies have shown the Assay improves patient outcomes and reduces overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacologist consultation.
Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.